Halozyme Therapeutics, Inc. · NASDAQ:HALO
Halozyme Therapeutics — 2019 Wells Fargo Healthcare Conference
24 slides from Halozyme Therapeutics's conference presentation, Sep 4, 2019
Slide 1: Building a Premier Oncology Biotech
2019 Wells Fargo Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 4, 2019
Slide 2: Forward-Looking Statements
Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such statements include possible activity, benefits and attr
Slide 3: Two Engines for Growth
Two Engines for Growth ENHANZE® PEGPH20 Proven ‘IV to Sub Q’ Late Stage Targeted Partnering Platform Oncology Asset Phase 3 Data Accelerating Partner Readout Currently Investment for Approvals Projected in Q4 2019 High Potential: Potential ~$1B Global ~$1B Annual Royalty Pancreas Indication Revenue
Slide 4: ENHANZE
Priore ENHANZE®
Slide 5: ENHANZE Offers Four Potential Paths for Differentiation and Value Creation for Partners
ENHANZE® Offers Four Potential Paths for Differentiation and Value Creation for Partners Reduced Treatment Burden 1 and Healthcare Costs DARZALEX® ALXN 1810 2 Potential for Competitive Differentiation BMS I/O Portfolio ARGX-113 3 New Intellectual Property and Exclusivity DARZALEX® Changing U.S. Reim
Slide 6: ENHANZE High-Growth Business
ENHANZE ® High-Growth Business 9 Agreements signed to date: Bristol-Myers Squibb Roche (Genentech), Baxalta, Agreement Terms Pfizer, Janssen, Eli Lilly, Abbvie Number of 11 BMS, Alexion, and argenx Targets Upfront $105M Milestones/ 3 Approved Products $160M Target 8 Targets in development today Roya
Slide 7: Near Term Catalysts: Potential Blockbuster Programs in Phase III in 2019
Near Term Catalysts: Project 3 Potential Blockbuster Programs in Phase III in 2019 2017 2018 2019 6 Products 11 Products 15 Products(1) 3 1 2 3 3 3 2 6 9 Approved and Commercialized Phase III 3 Commercialized Products Phase I 3 Products in Phase III 1 Projected by year-end as of January 9, 2019 6
Slide 8: Three Products Successfully Commercialized in Global Markets
Three Products Successfully Commercialized in Global Markets US ROW 7
Slide 9: ENHANZE Development Pipeline
ENHANZE® Development Pipeline Partner Product/Target Janssen DARZALEX® / Undisclosed Phase III in Undisclosed 2019 Regulatory Applications Ongoing Submitted Initiating BMS Anti-CD73 OPDIVO® ALXN1810 Phase I in argenx 2019 ARGX-113 Undisclosed PLUS 3 Potential New Phase I Starts in 2019 8
Slide 10: Daratumumab IV: Blockbuster Multiple Myeloma Treatment
Daratumumab IV: Blockbuster Multiple Myeloma Treatment Early Launch Data Compares Analyst Estimates for DARZALEX® Favorably with Other Multiple Myeloma Drug Launches ($ Millions) ($ Millions) Darzalex® 8000 2000 Empliciti® 7000 Kyprolis® 6000 1500 Ninlaro® Pomalyst® 5000 Revlimid® 4000 1000 3000 200
Slide 11: Daratumumab SC Regulatory Path
Daratumumab SC Regulatory Path Potential Benefits of Subcutaneous Formulation(1) • Faster infusion time being tested (3-5 minutes)(2) compared with 4-6 hour IV infusion, initially weekly • Well tolerated with fewer infusion related reactions (IRRs) than with IV(3) BLA/MAA Submissions Made in July 20
Slide 12: Perjeta/Herceptin Fixed Dose Combination with ENHANZE
Perjeta®/Herceptin® Fixed Dose Combination with ENHANZE®: Potential Regulatory Submissions First Half 2020 Potential Opportunity • PERJETA® indicated for use with Herceptin ® and Value proposition of Perjeta®/Herceptin® chemotherapy for adjuvant Fixed Dose SC with ENHANZE (3) treatment of patients w
Slide 13: ENHANZE: ~$1B Royalty Revenue Potential in 2027
ENHANZE®: ~$1B Royalty Revenue Potential in 2027 2019-2021 Potential Cumulative ~$1 Billion Milestones = $225M-$300M All other partner products Projected Royalties derived from products in phase 3 (2019) Trastuzumab, Rituximab, HyQvia 2018 2027 Projection based on approved products and assumes globa
Slide 14: ENHANZE: Royalties Exceed Pro Forma ENHANZE-only Operating Expenses
ENHANZE®: Royalties Exceed Pro Forma ENHANZE-only Operating Expenses 2019-2021 Potential Cumulative ~$1 Billion Milestones = $225M-$300M All other partner products Projected Royalties derived from products in phase 3 (2019) ENHANZE-only Operating Expense Trastuzumab, Rituximab, HyQvia 2018 2027 Proj
Slide 15: Accelerating ENHANZE Growth
Accelerating ENHANZE ® Growth New collaboration Daratumumab signed with argenx SC Regulatory 12 Targets in in 1Q 2019 is first Applications Development Existing with development- Submitted to FDA in 2019 Partnerships stage biotech and MAA Potential in Oncology, Pool of Potential New Rare Diseases, B
Slide 16: PEGPH20
Priore PEGPH20
Slide 17: Tumor HA Overexpression Associated with Shorter Survival in Pancreas Cancer
Tumor HA Overexpression Associated with Shorter Survival in Pancreas Cancer Retrospective Evaluation of Pancreatic Cancer Survival in ~50 Patients(1) HA-Low Median Survival: 24.3 months HA-High Median Survival: 9.3 months H.R. 2.6 p=0.037 1 Whatcott et al: Clin Cancer Res 2015, 21:3561-3568. HA stai
Slide 18: PEGPH20 Targets Hyaluronan (HA) in the Tumor Microenvironment
PEGPH20 Targets Hyaluronan (HA) in the Tumor Microenvironment In HA-High Tumor Animal Models, Removal of HA by PEGPH20 Demonstrated to: Decrease Decompress Increase Increase Increase intratumoral vasculature perfusion access for access for pressure therapeutics immune cells PEGPH20 17
Slide 19: Proprietary Test Developed in Phase II to Identify HA-High Patients
Proprietary Test Developed in Phase II to Identify HA- High Patients for Phase III • Partnered with Roche Tissue Analysis of OS in HA-High, Stage II HALO 202(1) Diagnostics (formerly Ventana) for Companion Diagnostic • Phase II Study HALO 202 key to develop Companion Diagnostic • 279 1L metastatic P
Slide 20: HALO-301 Study in Metastatic Pancreas Cancer
HALO-301 Study in Metastatic Pancreas Cancer 1L Metastatic PDA PEGPH20 + ABRAXANE® High-HA + gemcitabine (PAG) patients Primary Endpoint: N=~500 • Overall Survival (OS) based on 330 events Double-blind ABRAXANE® + gemcitabine (AG) + placebo 2:1 Randomization Expect topline data announcement by Decem
Slide 21: ~$1B Potential Opportunity in Pancreas Cancer
~$1B Potential Opportunity in Pancreas Cancer 65,000 Annual Diagnosed Metastatic Pancreatic Ductal Adenocarcinoma (PDA) U.S. and EU 5(1) ~$1B ~$1B Potential Global Sales Opportunity by 2027 in HA-High 25,000 Metastatic PDA(3,4) Estimated Number of HA-High Patients 35–40% of Population(2) 1 SEER 18 2
Slide 22: Ongoing Studies Evaluating Pan-tumor Potential of PEGPH20
Ongoing Studies Evaluating Pan-tumor Potential of PEGPH20 Tumor Stage Status Pancreas Cancer Phase 1b Dose Finding Enrollment (second-line) Started 2H 2017 completed Gall Bladder Cancer, Enrolling additional Cholangiocarcinoma 15 patients 21
Slide 23: 2019 Financial Guidance
2019 Financial Guidance May 2019 August 2019 $205M to $215M Net Revenue No Change -Royalties of $72-74M Operating Expenses $265 to $275M $255 to $265M Operating Expenses (excl. $225 to $235M $215 to 225M COGS) Operating Cash Burn ($45M) to ($55M) ($40M) to ($50M) Debt Repayment ~$90M No Change Year-
Slide 24: Outlook
Outlook • Growing ENHANZE momentum – ~$1 billion in annual royalty revenue potential by 2027 – Multiple near-term catalysts in a high margin business • Each pillar offers strong potential upside – ENHANZE: New deals plus up to $1 billion in lifetime milestones – PEGPH20: ~$1 billion global sales opp
Halozyme Therapeutics — 2019 Wells Fargo Healthcare Conference on 6ix